$Clene(CLNN.US$ on 29 Feb new exiting data will be presented at ACTRIMS Forum 2024.
1
3
$Intuitive Machines(LUNR.US$ last year the stock climed 40 just using the rumours as a ladder. This time it was a real rocket to the sky.
1
4
$Cogent Biosciences(COGT.US$ new data is comin for mastocytosis, the presentation is scheduled at AAAAI conference in a couple of days. And bezuclastinib soon will be a new standard of care for GIST.
$ARS Pharmaceuticals(SPRY.US$ new data will be presented at AAAAI meeting 23-26 Feb 2024
$BioCardia(BCDA.US$ 04 March 2024 new data from phase 3 and phase 1/2 trials will be presented at the Technology and Heart Failure Therapeutics Conference.
2
$Sangamo Therapeutics(SGMO.US$ 22 Feb 2024 positive results of IL23R - CAR will be announced at the ECCO 2024 meeting
$Ventyx Biosciences(VTYX.US$ 22 Feb 2024 Phase 2 positive results will be announced : VTS002 has been proven as well tollerated, met all primary and secondary endpoints, and has been found statistically superior to placebo.
$Akebia Therapeutics(AKBA.US$ 27 March - FDA approvale date. Vadadustat will be approved this time for the US market.
$Grifols(GRFS.US$ today announced positive topline results from AdFirst phase 3 study confirming the efficacy of fibrinogen concentrate in reducing intraoperative blood loss.
$SeaStar Medical(ICU.US$ FDA approval and a commence of the product are coming.
2